Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
Mechanisms driving the immunoregulatory function of cancer cells
A van Weverwijk, KE de Visser - Nature Reviews Cancer, 2023 - nature.com
Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …
activation state of immune cells, which impacts their progression and response to …
Epidemiology and risk factors for ovarian cancer
AT Ali, O Al-Ani, F Al-Ani - Menopause Review/Przegląd Menopauzalny, 2023 - termedia.pl
Ovarian cancer is a complex disease, mostly observed in postmenopausal women, and is
associated with poor survival rates. It is the sixth most common cancer and the fifth most …
associated with poor survival rates. It is the sixth most common cancer and the fifth most …
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma
D Barras, E Ghisoni, J Chiffelle, A Orcurto… - Science …, 2024 - science.org
Adoptive cell therapy (ACT) using ex vivo–expanded tumor-infiltrating lymphocytes (TILs)
can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a …
can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a …
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …
tumours. However, only a few patients respond to ICIs, which has generated considerable …
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer
NL Burdett, MO Willis, K Alsop, AL Hunt, A Pandey… - Nature …, 2023 - nature.com
High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous
recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to …
recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to …
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
The mechanisms regulating exhaustion of tumor-infiltrating lymphocytes (TIL) and
responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we …
responsiveness to PD-1 blockade remain partly unknown. In human ovarian cancer, we …
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Abstract Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging.
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …
The DNA damage response and inflammation in cancer
Genomic stability in normal cells is crucial to avoid oncogenesis. Accordingly, multiple
components of the DNA damage response (DDR) operate as bona fide tumor suppressor …
components of the DNA damage response (DDR) operate as bona fide tumor suppressor …
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
P Smith, T Bradley, LM Gavarró, T Goranova… - Nature …, 2023 - nature.com
The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain
unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a …
unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a …